Our services

ADC Review
is made possible by:




Milatuzumab-Doxorubicin (IMMU-110 / hLL1-Dox) Clinical Trials

Trial Title Study Record Detail Phase Sponsor/Collaborator
A Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma NCT01101594 Phase I / Phase II Immunomedics, Inc.

Last Editorial Review: July  15, 2016

Share

Manuscript Guidelines & Tips

Skip to toolbar